#Japan #Healthcare Innovation #Medical Imaging #Koganei #ASEMtech

ASEMtech Secures 250 Million Yen in Series A Funding

In a significant boost for innovative imaging technology, ASEMtech, based in Koganei, Tokyo, has raised 250 million yen in its Series A funding round conducted in April 2025. The financing was accomplished through a third-party allocation of new shares, with notable participation from companies such as Mirai Sozo Investments, BP Capital, Leo Electronics, and Quantum Leap Ventures.

This recent funding is aimed at accelerating clinical research efforts on a groundbreaking imaging device that allows for non-invasive histological evaluation. ASEMtech's core technology, known as the Acoustically Stimulated Electromagnetic method (ASEM), utilizes ultrasound to detect and analyze weak electromagnetic signals emitted by biological tissues and industrial materials. One of the main advantages of the ASEM method is its ability to visualize pathological tissue quality parameters that conventional ultrasound imaging cannot capture, such as the orientation and accumulation of collagen fibers.

The innovative capabilities of ASEMtech's technology offer significant advancements for early diagnosis and progression assessment of various conditions, including musculoskeletal disorders such as bone, tendon, and ligament diseases, as well as chronic diseases and cancers characterized by fibrosis in blood vessels and organs. This will enhance preventive medicine and contribute to the progress of personalized treatments. Additionally, ASEM technology holds promise in industrial settings for non-destructive detection of deterioration and morphological changes in materials used in sectors like steel and electric vehicles (EVs).

The funds raised in this financing round will specifically be utilized to speed up clinical studies focusing on the evaluation of collagen fibers pertinent to musculoskeletal diseases and vascular pathologies. ASEMtech will also focus on preparations aimed at obtaining regulatory approvals for its medical devices. Simultaneously, the company plans to actively market its non-destructive testing equipment developed during the seed funding round, targeting diverse needs across various customer sectors.

Understanding ASEM Technology

ASEM technology centers around the detection of electromagnetic signals – known as ASEM signals – induced by ultrasound in biological tissues and industrial materials. Unlike conventional ultrasound examinations that primarily assess internal structures and foreign objects, the ASEM method offers new insights into degradation and changes in crystalline structures within these materials, which helps visualize conditions that may not be detected by traditional methods.

The ability to non-invasively evaluate collagen accumulation and orientation opens new avenues for health screenings associated with musculoskeletal health and organ fibrosis in cancer and chronic diseases. This improved precision in early detection and assessment of disease progression points toward a path for enhanced preventive healthcare and sophisticated personalized treatment regimens.

Investor Insights

Comments from Stakeholders:

Ryohhei Takahashi, Executive Officer/Partner, Mirai Sozo Investments:
Mirai Sozo has proudly continued its support as a lead investor in this Series A round, following our participation in the seed round. We commend ASEMtech for its solid sales achievements in the non-medical device sector since the seed round and recognize its potential for future growth with a robust organization built for the long haul. We are eager to see ASEMtech grow in both medical and non-medical markets.

Koji Hamamura, Chief Capitalist, BP Capital:
Since the seed round, ASEMtech has consistently achieved key milestones under the leadership of CEO Kenshi Ikushima and has made significant strides toward transforming research from Tokyo University of Agriculture and Technology into real-world applications. We look forward to continued collaboration with new investors to ensure ASEMtech's growth.

Satoshi Yoshino, Executive Director, Leo Electronics:
As a firm that has closely partnered with ASEMtech from its inception, we recognize the vast potential within the ASEM phenomenon identified by CEO Ikushima. We are excited to enhance our partnership and focus collectively on expanding business opportunities that leverage both our manufacturing strengths and ASEMtech's technological advancements.

Hirotoshi Suwa, Representative Partner, Quantum Leap Ventures:
It is a pleasure to join ASEMtech on this journey, and we believe the ASEM method will bring transformative value to the medical and infrastructure sectors, driving further growth for the company.

ASEMtech's Commitment to Innovation

Kenshi Ikushima, CEO of ASEMtech:
At ASEMtech, our mission is to deliver innovative solutions that leverage our ultrasound-based technology, ASEM, across both healthcare and industrial sectors. The proceeds from this funding round will propel our clinical research aimed at musculoskeletal and vascular diseases and mark a significant step toward regulatory approval for our medical imaging devices. We are also committed to actively expanding our offerings of non-destructive testing equipment tailored for infrastructure maintenance and quality assessment.

With a focus on extending healthy lifespans and fostering a safe, secure society, we remain dedicated to advancing research and accelerating the societal implementation of our groundbreaking technologies. ASEMtech is poised to meet and exceed expectations as it continues its journey.

About ASEMtech Inc.

• - Company Name: ASEMtech Inc.
• - Headquarters: 24-16 Nakacho 2-chome, Koganei, Tokyo, Japan, Tokyo University of Agriculture and Technology Campus
• - Founded: November 2023
• - Business Focus: Research, development, design, manufacturing, sales, and rental of medical diagnostic devices pertaining to ASEM technology; industrial non-destructive testing devices related to ASEM technology.
• - Website: ASEMtech